高压氧对局灶性脑缺血后细胞凋亡的影响及其机制

目的：观察不同时间点高压氧（HBO）治疗对短暂性脑缺血的作用,并探讨其对细胞凋亡的影响。方法：在客观监测局部脑血流的条件下,大鼠经历短暂脑缺血后3h,6h,12h应用HBO治疗,24h后行神经功能评分和梗死体积测定,免疫组化染色各组Bcl-2、Bax、活性Caspase-3、活性Caspase-9以及TUNEL法检测细胞凋亡。结果：缺血后3h HBO治疗减少70％梗死体积,缺血后6hHBO治疗则减少梗死体积约44％,早期应用HBO治疗增加半暗带区细胞内Bcl-2的表达,减少活性Caspase-9和活性Caspase-3以及TUNEL阳性细胞数;缺血后12h应用HBO治疗却恶化神经功能,扩大梗死范围,而对上述凋亡各指标无影响。结论：HBO治疗短暂性局灶脑缺血具有时间窗,应争取在缺血后6h内应用HB0治疗,其早期治疗的神经保护作用与抑制细胞凋亡有关。     

厄贝沙坦对脑损伤大鼠神经细胞凋亡的影响

目的:研究血管紧张素I受体(AT1)抑制剂厄贝沙坦对侧位液压脑损伤模型大鼠神经细胞凋亡的影响。方法:利用改良的侧位液压损伤装置建立大鼠颅脑损伤(TBI)模型,术前及术后给予厄贝沙坦治疗,用激光多普勒测定局部脑区血流(r CBF)的变化,术前及术后1、3、5和7d利用神经功能评分评估大鼠神经功能损伤,利用TUNEL染色检测大鼠脑细胞凋亡情况,利用Western Blot检测大鼠脑组织损伤周围区域活性caspase 3的表达。结果:与正常值相比,TBI手术后损伤局部脑区r CBF下降至30%(P0.05),神经功能评分显著降低(P0.05),损伤区周围脑组织TUNEL阳性细胞明显增多,活性caspase 3的表达显著增加(P0.05)。厄贝沙坦治疗组大鼠r CBF显著高于单纯TBI组,梗死区面积显著缩小,神经功能得到明显改善,损伤区周围脑组织TUNEL阳性细胞和活性caspase 3表达下降(P均0.05)。结论:厄贝沙坦预处理能够通过抑制凋亡发挥神经保护作用。     

局部亚低温联合硫酸镁对局灶性脑缺血大鼠的保护作用

目的:探讨联合应用局部亚低温(32-35℃)及硫酸镁对局灶性脑缺血大鼠的保护作用及其可能机制。方法:通过线栓法建立大鼠大脑中动脉阻塞(MCAO)模型,将40只雄性Wistar大鼠随机分为假手术组、常温组、亚低温组、硫酸镁组、亚低温+硫酸镁组,每组8例,采用Longa神经功能评分、TTC染色、TUNEL技术,检测和比较各组脑缺血后大鼠的神经功能、脑梗死体积、凋亡细胞数。结果:与常温组相比,亚低温组与亚低温+硫酸镁组的梗死体积、神经功能评分、凋亡细胞数均明显降低,差异有显著意义(P0.05);而与亚低温组相比,亚低温+硫酸镁组局灶脑缺血大鼠的脑梗死体积、神经功能评分、凋亡细胞数均显著减少,差异有显著意义(P0.05)。结论:与单独应用亚低温相比,局部亚低温与硫酸镁联合应用,对局灶性脑缺血大鼠可发挥更有效的脑保护作用,其机制可能与抑制脑缺血后凋亡有关。     

亚低温联合镁剂对脑缺血再灌注大鼠保护作用的研究

目的:rt-PA溶栓为缺血性卒中最有效的治疗方法,脑血流再通后挽救濒临死亡的神经细胞同时,也可能发生更为严重而持久的脑缺血再灌注损伤。本研究探讨联合应用局部亚低温(32-35℃)及硫酸镁对局灶性脑缺血再灌注大鼠的保护作用及其可能机制。方法:通过线栓法建立大鼠大脑中动脉阻塞(MCAO)及再通模型,将50只雄性Wistar大鼠随机分为假手术组、常温组、亚低温组、硫酸镁组、亚低温+硫酸镁组,每组10例,采用Longa神经功能评分、TTC染色、干湿重法、TUNEL技术,检测和比较各组脑缺血再灌注后大鼠的神经功能、脑梗死体积、脑组织含水量及凋亡细胞数。结果:与常温组相比,亚低温组与亚低温+硫酸镁组的梗死体积、神经功能评分、脑组织含水量、凋亡细胞数均明显降低,差异有显著意义(P0.05);而与亚低温组相比,亚低温+硫酸镁组局灶脑缺血大鼠的脑梗死体积、神经功能评分、脑组织含水量、凋亡细胞数均显著减少,差异有显著意义(P0.05)。结论:与单独应用亚低温相比,局部亚低温与硫酸镁联合应用,对局灶性脑缺血再灌注大鼠可发挥更有效的脑保护作用。其机制可能与抑制脑缺血再灌注后凋亡及减轻脑水肿有关。二者联用可能为缺血性卒中患者提供一种减轻溶栓后再灌注损伤的有效脑保护方法。     

促红细胞生成素对大鼠局灶性脑缺血再灌注神经元的保护作用及P53蛋白的表达

目的:探讨促红细胞生成素(Epo)对大鼠局灶性脑缺血再灌注神经细胞的保护作用.方法:60只SD大鼠随机分为缺血再灌注Epo治疗组(又分为高剂量A组、低剂量B组)、缺血再灌注组(C组)及假手术组(D组),采用大脑中动脉线栓法制备大鼠局灶性脑缺血再灌注模型.参考Longa的5分制法在大鼠麻醉清醒后进行评分,TTC染色法观察线栓侧的梗死体积,并检测脑组织含水量的变化,HE染色法观察脑缺血再灌注后脑组织的病理变化,TUNEL法观察神经细胞凋亡情况,western blot法观察p53蛋白的表达变化.结果:对照组比较,大鼠脑缺血再灌注后出现不同程度的脑梗死,24h后缺血中心区及周围区均可见到p53蛋白表达.缺血再灌注6h内给予Epo可显著改善大鼠神经功能评分,减少梗死体积及脑组织含水量,减轻病理学变化及神经细胞凋亡.结论:Epo通过调控神经细胞凋亡、改善缺血再灌注损伤而发挥脑保护作用,P53蛋白参与缺血再灌注后神经细胞凋亡机制.     

UCF-101对大鼠局灶性脑缺血再灌注后JNK和ERK活性的影响

目的:探讨UCF-101对局灶性脑缺血再灌注大鼠脑内c-Jun氨基末端激酶(JNK)和胞外信号调节酶(ERK)活性的影响,进一步探讨UCF-101对局灶性脑缺血再灌注损伤脑保护作用的机制。方法:采用大脑中动脉线栓法(MCAO)建立大鼠局灶性脑缺血再灌注模型,随机分为假手术组,缺血再灌注组,UCF组,应用TTC检测大鼠脑梗死体积,TUNEL法检测神经元凋亡,Western blot检测ERK和JNK的活性。结果:UCF-101可下调脑缺血再灌注大鼠脑组织JNK蛋白的活性,上调ERK蛋白的活性,并降低梗死体积、坏死和凋亡细胞数。结论:UCF-101对大鼠局灶性脑缺血再灌注损伤有保护作用,抑制JNK凋亡通路、促进ERK生存通路,从而减轻细胞凋亡是其脑保护机制之一。     

早期跑步运动对大鼠脑缺血/再灌注损伤后神经行为与神经元凋亡的影响

目的: 探讨早期跑步运动对大鼠脑缺血后神经行为与神经元凋亡的影响。方法:雄性SD大鼠随机分为4组:假手术+安静组(Sham-St、假手术+运动组(Sham-Ex)、缺血(大脑中动脉闭塞(MCAO) +运动组((MCAO -Ex)和缺血+安静组(MCAO-St),每组15只。MCAO-Ex 和 MCAO-St 组大鼠行MCAO 60 min,再灌注2 d后,MCAO-Ex 和Sham-Ex大鼠在跑步机上进行5 d的30 min/d跑步运动(15 m/min),之后进行神经行为学评价,最后大鼠断头取脑进行TTC方法染色,评估各组大鼠梗死体积以及缺血半影Caspase-3和TUNEL阳性细胞表达水平。结果:与Sham-St相比,MCAO-St和MCAO-Ex大鼠缺血半影区Caspase-3表达均显著升高 (P＜0.05);与MCAO-St 组大鼠相比,MCAO-Ex组大鼠脑梗死体积明显减少,大鼠神经功能评分明显改善,大鼠缺血半影区Caspase-3和TUNEL阳性细胞表达水平显著降低 (P＜0.05)。结论: 早期运动可能通过抑制大鼠脑缺血后神经元凋亡发挥神经保护作用。     

骨髓间充质干细胞移植对大鼠脑缺血再灌注损伤Livin和Caspase-3表达的影响

目的探讨骨髓间充质干细胞（BMSCs）移植对大鼠脑缺血再灌注损伤海马区凋亡相关基因Livin和Caspase-3表达及神经元细胞凋亡的影响。方法实验动物分为假手术组、模型组和BMSCs组,进行神经功能评分,应用TTC法检测脑梗死体积,追踪PKH26标记的移植BMSCs,应用免疫组化方法和Western blot检测Livin、Caspase-3蛋白表达,应用TUNEL法检测细胞凋亡。结果 PKH26标记的BMSCs在海马区有表达。与模型组比较,BMSCs组神经功能评分显著降低（P〈0.05）,脑梗死体积显著减少（P〈0.05）。BMSCs组与模型组相比Livin蛋白表达显著增高（P〈0.05）,Caspase-3蛋白表达明显下降（P〈0.05）,神经元细胞凋亡指数显著降低（P〈0.05）。结论 BMSCs对脑缺血再灌注损伤具有保护作用,其作用机制可能与上调Livin表达,下调Caspase-3表达,抑制细胞凋亡有关。     

钙敏感受体在大鼠脑缺血再灌注损伤时细胞凋亡中的作用

目的:评价钙敏感受体在大鼠脑缺血再灌注损伤时细胞凋亡中的作用。方法:健康成年雄性Wistar大鼠60只,体重250～300 g,采用随机数字表法分为3组(n=20):假手术组(S组)、脑缺血再灌注组(I/R组)和钙敏感受体拮抗剂组(N组)。I/R组和N组采用线栓法经左侧颈外-颈内动脉插线制备大鼠脑缺血再灌注损伤模型,于脑缺血前10 min尾静脉注射等容量二甲基亚砜和钙敏感受体拮抗剂NPS-89636 1 mg/kg。于再灌注24 h时行神经功能评分,随后处死大鼠取脑组织,测定MDA含量和SOD活性,采用TUNEL法观察神经细胞凋亡情况,计算神经细胞凋亡指数,免疫组化法检测Caspase-3阳性细胞的表达,Western blot法检测Caspase-3蛋白的表达。结果:I/R组和N组MDA含量、神经细胞凋亡指数、Caspase-3阳性细胞和Caspase-3蛋白表达水平高于S组,神经功能评分和SOD活性低于S组,差异有统计学意义(P0.05);N组MDA含量、神经细胞凋亡指数、Caspase-3阳性细胞和Caspase-3蛋白表达水平低于I/R组,神经功能评分和SOD活性高于I/R组,差异有统计学意义(P0.05)。结论:钙敏感受体参与大鼠脑缺血再灌注损伤和细胞凋亡的发生。     

缺血后处理对大鼠局灶性脑缺血再灌注损伤时TLR4信号通路表达的影响

目的：观察缺血后处理对大鼠局灶性脑缺血再灌注损伤后TLR4通路表达的影响。方法：成年健康雄性SD大鼠110只,随机分为假手术组（sham组）（n=10）、缺血再灌注组（I／R组）和后处理组（IP组）,后两组又依据缺血再灌注6h、12h、24h、48h、72h不同的时间点再分五个亚组。对各组行神经行为学评分,脑组织梗死体积测量,TUNEL技术检测神经细胞凋亡的情况,免疫组织化学技术观察各组大鼠脑组织TLR4、NF—KB和TNF—a蛋白的表达,原位杂交方法检测各组大鼠脑组织TLR4mRNA、NF-KBmRNA的表达。结果：缺血后处理可下调TLR4、NF-KB、TNF-a细胞炎性因子的表达,抑制细胞凋亡、减少脑梗死体积,改善神经行为。结论：后处理可通过抑制TLR4信号通路表达,减少脑梗死体积,改善神经功能。     

Quercetin Protects Against Oxidative Stress Associated Damages in a Rat Model of Transient Focal Cerebral Ischemia and Reperfusion

Experimental studies have demonstrated that oxidative stress and apoptosis play an important role in cerebral ischemic pathogenesis and may represent a target for treatment. The purpose of this study was to determine whether the quercetin dihydrate (Q) protects against cerebral ischemia neuronal damage. Male Wistar rats were subjected to transient middle cerebral artery occlusion (MCAO) for 2?h and reperfused for 72?h. Quercetin (30?mg/kg, i.p) was administrated 30?min before the onset of ischemia and after the ischemia at interval of 0, 24, 48, and 72?h. The administration of Q showed marked reduction in infarct size, reduced the neurological deficits in terms of behaviors, suppressed neuronal loss and diminished the p53 expression in MCAO rats. Q was found to be successful in upregulating the antioxidant status and lowering the TBARS level. Conversely, the elevated activity of poly (ADP-ribose) polymerase (PARP), and activity of caspase-3 in MCAO group was attenuated significantly in Q treated group when compared with MCAO group. Our study reveals that Q, as a powerful antioxidant, could prevent free radicals associated oxidative damage and morphological changes in the MCAO rats. Thus, it may have a therapeutic value for the treatment of stroke.     

Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke

Statins have recently been shown to exert neuronal protection in ischemic stroke. Reactive oxygen species, specifically superoxide formed during the early phase of reperfusion, augment neuronal injury. NADPH oxidase is a key enzyme for superoxide production. The present study tested the hypothesis that atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in transient focal ischemia. Transient focal ischemia was created in halothane-anesthetized adult male Sprague-Dawley rats (250-300 g) by middle cerebral artery occlusion (MCAO). Atorvastatin (Lipitor, 10 mg/kg sc) was administered three times before MCAO. Infarct volume was measured by triphenyltetrazolium chloride staining. NADPH oxidase enzymatic activity and superoxide levels were quantified in the ischemic core and penumbral regions by lucigenin (5 microM)-enhanced chemiluminescence. Expression of NADPH oxidase membrane subunit gp91(phox) and membrane-translocated subunit p47(phox) and small GTPase Rac-1 was analyzed by Western blot. NADPH oxidase activity and superoxide levels increased after reperfusion and peaked within 2 h of reperfusion in the penumbra, but not in the ischemic core, in MCAO rats. Atorvastatin pretreatment prevented these increases, blunted expression of membrane subunit gp91(phox), and prevented translocation of cytoplasmic subunit p47(phox) to the membrane in the penumbra 2 h after reperfusion. Consequently, cerebral infarct volume was significantly reduced in atorvastatin-treated compared with nontreated MCAO rats 24 h after reperfusion. These results indicate that atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in transient focal ischemia.     

Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation

Oxidative stress induced cell injury is reported to contribute to the pathogenesis of cerebral ischemia. Reactive oxygen species such as hydrogen peroxide (H2O2) and superoxide radical along with nitric oxide and peroxynitrite generated during ischemia-reperfusion injury, causes the overactivation of poly (ADP-ribose) polymerase (PARP) leading to neuronal cell death. In the present study we have evaluated the effects of PARP inhibitor, 8-hydroxy-2 methyl-quinazolin-4-[3H]one (NU1025) in H2O2 and 3-morphilinosyndonimine (SIN-1) induced cytotoxicity in PC12 cells as well as in middle cerebral artery occlusion (MCAO) induced focal cerebral ischemia in rats. Exposure of PC12 cells to H2O2 (0.4 mM) and SIN-1 (0.8 mM) resulted in a significant decrease in cell viability after 6 h. Pretreatment with NU1025 (0.2 mM) restored cell viability to approximately 73 and 82% in H2O2 and SIN-1 injured cells, respectively. In MCAO studies, NU1025 was administered at different time points (1 h before reperfusion, immediately before reperfusion, 3 h after reperfusion and 6 h after reperfusion). NU1025 at 1 and 3 mg/kg reduced total infarct volume to 25% and 45%, respectively, when administered 1 h before reperfusion. NU1025 also produced significant improvement in neurological deficits. Neuroprotection with NU1025 was associated with reduction in PAR accumulation, reversal of brain NAD depletion and reduction in DNA fragmentation. Results of this study demonstrate the neuroprotective activity of NU1025 and suggest its potential in cerebral ischemia.     

Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-κB

Taurine is reported to reduce tissue damage induced by inflammation and to protect the brain against experimental stroke. The objective of this study was to investigate whether taurine reduced ischemic brain damage through suppressing inflammation related to poly (ADP-ribose) polymerase (PARP) and nuclear factor-kappaB (NF-κB) in a rat model of stroke. Rats received 2 h ischemia by intraluminal filament and were then reperfused. Taurine (50 mg/kg) was administered intravenously 1 h after ischemia. Treatment with taurine markedly reduced neurological deficits, lessened brain swelling, attenuated cell death, and decreased the infarct volume 72 h after ischemia. Our data showed the up-regulation of PARP and NF-κB p65 in cytosolic fractions in the core and nuclear fractions in the penumbra and core, and the increases in the nuclear poly (ADP-ribose) levels and the decreases in the intracellular NAD⁺ levels in the penumbra and core at 22 h of reperfusion; these changes were reversed by taurine. Moreover, taurine significantly reduced the levels of tumor necrosis factor-α, interleukin-1β, inducible nitric oxide synthase, and intracellular adhesion molecule-1, lessened the activities of myeloperoxidase and attenuated the infiltration of neutrophils in the penumbra and core at 22 h of reperfusion. These data demonstrate that suppressing the inflammatory reaction related to PARP and NF-κB-driven expression of inflammatory mediators may be one mechanism of taurine against ischemic stroke.     

The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats

Leukocyte infiltration is viewed as a pharmacological target in cerebral ischemia. We previously reported that reparixin, a CXCL8 receptor blocker that inhibits neutrophil infiltration, and related molecules can reduce infarct size in a rat model of transient middle cerebral artery occlusion (MCAO). The study aims were to compare the effects of reparixin in transient and permanent MCAO using varied treatment schedules and therapeutic windows to evaluate effects on long-term neurological deficits and late inflammatory response. Reparixin, administered for 1 to 3 days, 3.5 to 6 h after MCAO, ameliorates neurological function recovery and inhibits long-term inflammation. The infarct size reduction at 24 h, evaluated by TTC staining, is more pronounced in transient MCAO. MRI analysis identified a decrease in the progression of infarct size by reparixin that was more evident at 48 h in permanent MCAO, and was associated with a significantly improved recovery from long-term neurological deficits.     

Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke

In patients with stroke and neurodegenerative diseases, overactivation of poly(ADP-ribose) polymerase-1 (PARP-1) causes harmful effects by inducing apoptosis, necrosis, neuroinflammation, and immune dysregulation. The current study investigated the neuroprotective effect of a novel PARP-1 inhibitor, JPI-289, in an animal model of ischemic stroke. A transient middle cerebral artery occlusion (tMCAO, 2 h) model was used to determine the therapeutic effect and the most effective dose and time window of administration of JPI-289. We also investigated the long-term outcomes of treatment with JPI-289 by diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) MRI and by measuring neurological function at 24 h, 7 days, and 28 days after MCAO. The most effective dose and time window of administration of JPI-289 was 10 mg/kg administered 2 h after MCAO with reperfusion. Twenty-four hours after MCAO, infarct volume was reduced by 53% and the number of apoptotic cells was reduced by 56% compared with control. JPI-289 also reduced infarct volume by 16% in the permanent MCAO model. In an MRI-based study, initial infarct volume, as measured using DWI, was similar in the control and JPI-289-treated groups. However, infarct volume and brain swelling were significantly reduced in the group treated with JPI-289 (2 h) at 24 h and 7 days after MCAO. Neurological functions also improved in the group treated with JPI-289 (2 h) until 28 days after MCAO. Inhibition of PARP-1 has neuroprotective effects (reduction of infarct volume and brain swelling) in both tMCAO and pMCAO models of ischemic stroke.     

产前应激对子代大鼠脑缺血/再灌注后星形胶质细胞的影响

目的：探讨产前应激对雄性子代大鼠大脑中动脉缺血/再灌注后星形胶质细胞的影响。方法：SD孕鼠随机分为有产前应激处理（妊娠第15到21天每日3次限制活动）和无产前应激处理,并对其雄性子代大鼠采用线栓法制备大脑中动脉闭塞（MCAO）模型,共分为产前应激+假手术组、MCAO模型组、产前应激+MCAO组（n=10）,于再灌注后第5天检测脑梗死体积,免疫荧光双标染色检测缺血灶边缘区星形胶质细胞形态及促红细胞生成素肝细胞受体A4（EphA4）和胶质纤维酸性蛋白（GFAP）的共表达情况,并采用Western blot检测EphA4、GFAP和神经蛋白聚糖（Neurocan）蛋白表达。结果：产前应激+MCAO组子代大鼠脑梗死体积百分比、EphA4、GFAP和Neurocan蛋白表达均较MCAO组显著增加（P均<0.05）,且GFAP阳性细胞形态学改变及EphA4/GFAP共表达也较MCAO组明显。结论：产前应激可能改变子代大鼠脑缺血/再灌注后星形胶质细胞上EphA4受体的表达,促进星形胶质细胞活化,产生神经蛋白聚糖。     

Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury

The objective of the present study was to examine the role of the angiotensin II type 1 receptor (AT(1)-R) in the diabetes-aggravated oxidative stress and brain injury observed in a rat model of combined diabetes and focal cerebral ischemia. Diabetes was induced by an injection of streptozotoxin (STZ; 55 mg/kg iv) at 8 wk of age. Two weeks after the induction of diabetes, some animals received continuous subcutaneous infusion of the AT(1)-R antagonist candesartan (0.5 mg.kg(-1).day(-1)) for 14 days. Focal cerebral ischemia, induced by middle cerebral artery occlusion/reperfusion (MCAO), was conducted at 4 wk after STZ injection. Male Sprague-Dawley rats (n = 189) were divided into five groups: normal control, diabetes, MCAO, diabetes + MCAO, and diabetes + MCAO + candesartan. The major observations were that 1) MCAO produced typical cerebral infarction and neurological deficits at 24 h that were accompanied by elevation of NAD(P)H oxidase gp91(phox) and p22(phox) mRNAs, and lipid hydroperoxide production in the ipsilateral hemisphere; 2) diabetes enhanced NAD(P)H oxidase gp91(phox) and p22(phox) mRNA expression, potentiated lipid peroxidation, aggravated neurological deficits, and enlarged cerebral infarction; and 3) candesartan reduced the expression of gp91(phox) and p22(phox), decreased lipid peroxidation, lessened cerebral infarction, and improved the neurological outcome. We conclude that diabetes exaggerates the oxidative stress, NAD(P)H oxidase induction, and brain injury induced by focal cerebral ischemia. The diabetes-aggravated brain injury involves AT(1)-Rs. We have shown for the first time that candesartan reduces brain injury in a combined model of diabetes and cerebral ischemia.